ClinicalTrials.gg
RecruitingNCT07043751Updated Jan 21, 2026

A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors

A Phase 1 interventional study of TQB6411 injection in Advanced Malignant Tumors, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Recruiting at 19 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
216
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

TQB6411 for injection is an antibody-conjugated drug (ADC) targeting EGFR/c-Met. After injecting blood intravenously, the antibody part of this product binds to the surface of EGFR and c-Met on tumor cells to block the activation of EGFR and c-Met signaling pathways. The ADC is enzymatically transported to the lysosome. The linker releases toxins after enzyme cleavage, resulting in DNA damage and cell death. TQB6411 for injection is intended for the treatment of advanced malignant tumors.

02

Conditions studied

  • Advanced Malignant Tumors
03

In context

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. is the lead sponsor of 53 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subjects voluntarily joined the study, signed an form, and had good compliance;
  • 18 years old≤age age≤75 years old (calculated based on the date of signing the informed consent form);
  • (ECOG) score 0\~1 point;
  • Expected survival is greater than 12 weeks;
  • According to the v1.1 standard, there is at least one evaluable tumor lesion in the dose escalation stage, and at least one in the dose expansion stage;
  • Laboratory examination standards that meet the program requirements (no use of hematopoietic stimulator drugs for correction within 7 days);
  • Subjects who failed or were intolerant of standard treatment;
  • Subject requirements for the dose expansion stage: advanced NSCLC; colon cancer; recurrent/metastatic esophageal squamous cell carcinoma; recurrent/metastatic nasopharyngeal carcinoma; advanced malignant solid tumor;
  • Can provide tumor tissue specimens that meet the requirements for immunohistochemical testing;
  • Women of childbearing age should agree that effective must be adopted during the study period and within 6 months after the end of the study, and that the serum or urine pregnancy test will be negative within 7 days before the study enrollment; men should agree that effective contraception must be adopted within 6 months after the end of the study period;

Exclusion criteria

Exclusion Criteria:

  • Have appeared or are currently suffering from other malignant tumors;
  • There are diseases that affect intravenous injection and intravenous blood collection;
  • The adverse reactions of previous treatments failed to recover to V5.0 grade score ≤1, except for toxicity without safety risk, such as grade 2 hair loss, grade 2 peripheral nerve toxicity, grade 2 anemia, non-clinical significance and asymptomatic grade 2 laboratory abnormalities, stable hypothyroidism with hormone replacement therapy;
  • Those who have received major surgical treatment, obvious traumatic injury or major surgery during the expected study treatment within 4 weeks before the first medication (except for the surgery stipulated in the program), or have long-term uncured wounds or fractures;
  • Subjects with any bleeding or bleeding events ≥CTC AE grade 3 within 4 weeks before the first dose;
  • Arterial/venous thrombosis events occurred within 6 months before the first dose;
  • People with active viral hepatitis and poor control;
  • People infected with active syphilis who need treatment;
  • There is a history of active tuberculosis, idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonia/radio-pneumonia that needs treatment, or active pneumonia with obvious clinical symptoms, and interstitial lung disease (ILD) that needs treatment, or currently associated with interstitial lung disease;
  • Those with a history of abuse of psychotropic substances and cannot quit or have mental disorders;
  • Preparing for or having previously received bone marrow transplants or solid organ transplants;
  • Have a history of hepatic brain disease;
  • Suffering from major cardiovascular disease;
  • Severe infection that is active or uncontrollable (≥CTC AE grade 2 infection);
  • People who require hemodialysis or peritoneal dialysis if renal failure is required;
  • Have a history of immunodeficiency, including -positive or other acquired, congenital immunodeficiency diseases;
  • Subjects who have poorly controlled diseases and need to use agents or systemic hormones to achieve immunosuppressive purposes and still need to continue using them within 7 days before the first dose (except for daily dose of \<10 mg prednisone or other therapeutic hormones);
  • People with epilepsy and need treatment;
  • Poor diabetes control [fasting blood sugar (FBG) > 10mmol/L];
  • Tumor-related symptoms and treatment: subjects who have received chemotherapy, immunotherapy, small molecule targeted drugs, etc. within 3 weeks before the first dose, or are still in the 5 half-life of the drug; within 1 week before the first dose, they have received Chinese patent medicine treatment with anti-tumor indications in the National Medical Products Administration (NMPA) approved drug instructions; imaging (CT or MRI) shows that the tumor has invaded important blood vessels or the researchers judged that the tumor is very likely to invade important blood vessels during the subsequent study and causing fatal major bleeding; if it is not controlled, pleural effusion, pericardial effusion or moderate and severe ascites that still require repeated drainage; known to suffer from spinal cord compression, meningeal /cancer meningitis, accompanied by symptoms or symptoms/image control time is less than 4 weeks;
  • Known allergies to research drugs or ;
  • Have received previous treatment for Epidermal Growth Factor Receptor (EGFR)/c-Mesenchymal-epithelial transition dual anti-ADC drugs;
  • Those who participated in and used other anti-tumor clinical trial drugs within 4 weeks before the first medication;
  • According to the researcher's judgment, there are situations that seriously endanger the safety of the subject or affect the subject's completion of the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
216 participants (estimated)

Study arms

  • Experimental
    TQB6411 injection

    Intravenous injection, the dosage begins on the first day of each cycle, and one treatment cycle every 3 weeks; the dose group is between 0.8 mg/kg-8 mg/kg.

    Drug: TQB6411 injection

Interventions

  • TQB6411 for injection is an antibody-conjugated drug (ADC) targeting EGFR/c-Met. After injecting intravenously, the antibody part of this product binds to the EGFR and c-Met on the surface of tumor cells to block the activation of EGFR and c-Met signaling pathways. The ADC is enrolled and transported to the lysosome through cells. The linker releases toxins after enzyme cleavage, resulting in DNA damage and cell death.

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity

    Dosage-limiting toxicity refers to any of the following events that researchers and sponsors believe to be related to the treatment of TQB6411 for injection (including positively related, likely related, and possible related) (except for special instructions, the degree of adverse events is evaluated in accordance with National Cancer Institute (NCI) Common Terminology Criteria (CTC) for Adverse Events (AE) v5.0.

    Time frame: Up to24 months

  2. Maximum Tolerated Dose

    Defined as the highest dose in less than 33% of subjects with dose-limiting toxicity (DLT).

    Time frame: Up to24 months

  3. Phase II recommended dose

    The recommended dose for subsequent phase II studies will be determined based on Maximum Tolerated Dose (MTD), Pharmacokinetics (PK), preliminary efficacy and safety.

    Time frame: Up to24 months

  4. Rate and severity of adverse events

    Rate and severity of adverse events

    Time frame: Up to24 months

Secondary outcomes

  1. Peak drug concentration (Cmax)

    It refers to the highest blood drug concentration achieved after administration of TQB6411 for injection.

    Time frame: Within 14 days after administration

  2. Area under the concentration-time curve from time zero to the last measurable concentration time t (AUC0-t)

    Area under the concentration-time curve from time zero to the last measurable concentration time t (AUC0-t).

    Time frame: Within 14 days after administration

  3. Area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞)

    Area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞).

    Time frame: Within 14 days after administration

  4. Peak time (Tmax)

    It refers to the time when the maximum blood drug concentration is reached after administration of TQB6411 for injection.

    Time frame: Within 14 days after administration

  5. Overall response rate (ORR)

    Proportion of subjects with best response as Partial relief (PR), Complete Response (CR).

    Time frame: Up to 24 months

  6. Disease Control Rate (DCR)

    Proportion of subjects with best response as Complete Response (CR), Partial relief (PR), Stable Disease (SD).

    Time frame: Up to 24 months

  7. Progression-free survival (PFS)

    The time between the first dose of the trial drug and the date of first definite disease progression or death (from any cause), whichever occurs first.

    Time frame: Up to 24 months

  8. Overall survival (OS)

    Time from first dose of study drug to date of death from any cause.

    Time frame: Up to 24 months

  9. The incidence of antibiotic-resistant antibodies (ADA) and neutralizing antibodies (NAbs)

    The incidence of antibiotic-resistant antibodies (ADA) and neutralizing antibodies (NAbs)

    Time frame: Up to 24 months

07

Study locations

1 of 19 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Dec 2027, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2025
First posted
Jun 29, 2025
StartActual
Jul 15, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Jun 2028
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07043751
Responsible party
Sponsor
First posted
Jun 29, 2025
Start date
Jul 15, 2025
Primary completion
Dec 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Jan 21, 2026

Study contacts

Shengxiang Ren, Doctor
Contact
harry_ren@126.com
13816756732
Feng Wang, Doctor
Contact
fengwang010@163.com
13938244776

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQB6411

Start the discussion